Blurbs

Analysts’ Top Healthcare Picks: Emergent Biosolutions (EBS), Viking Therapeutics (VKTX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Emergent Biosolutions (EBSResearch Report) and Viking Therapeutics (VKTXResearch Report) with bullish sentiments.

Emergent Biosolutions (EBS)

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Emergent Biosolutions, with a price target of $65.00. The company’s shares closed last Thursday at $36.61.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 8.4% and a 39.7% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Mountain Crest Acquisition II, and Arrowhead Pharmaceuticals.

Emergent Biosolutions has an analyst consensus of Hold, with a price target consensus of $50.25.

See Insiders’ Hot Stocks on TipRanks >>

Viking Therapeutics (VKTX)

Maxim Group analyst Naz Rahman maintained a Buy rating on Viking Therapeutics yesterday and set a price target of $10.00. The company’s shares closed last Thursday at $2.42, close to its 52-week low of $2.15.

According to TipRanks.com, Rahman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -35.6% and a 7.5% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Neurosense Therapeutics Ltd., and Processa Pharmaceuticals.

Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $18.20, implying a 731.1% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $21.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EBS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos